The blockers of exosomes SIRP α and CD47 can enhance the phagocytic function of cancer cells, suggesting that targeting SIRP α with antibodies presents a promising immunotherapy approach for treating tumors exhibiting high expression of SIRP α, such as renal cell carcinoma and melanoma (Yanagita et al., 2017). The gene discussed is SIRPA; the disease is melanoma.